Windlas Biotech Reports Q2 Standalone Net Profit of ₹18.05 Crore Versus ₹17.80 Crore YoY

Market snapshot: Windlas Biotech Limited announced its standalone financial results for the second quarter ended September 30, 2026. The company achieved a standalone net profit of ₹18.05 crore, demonstrating stable earnings compared to the corresponding period of the previous fiscal year.

Data Snapshot

• Standalone net profit reached ₹18.05 crore for the quarter ended September 30, 2026.
• Standalone net profit stood at ₹17.80 crore in the same quarter of the previous financial year.

What's Changed

• Standalone net profit increased by ₹0.25 crore YoY (derived: ₹18.05 crore vs ₹17.80 crore).
• YoY growth rate in standalone net profit recorded at approximately 1.40% (derived: ₹18.05 crore vs ₹17.80 crore).

Key Takeaways

• Windlas Biotech sustained single-digit bottom-line growth during Q2 on a standalone basis.
• Net profit reached ₹18.05 crore against ₹17.80 crore in the year-ago period.
• The earnings stability reflects persistent demand for formulation manufacturing and CDMO capabilities.

SAHI Perspective

Windlas Biotech's Q2 earnings highlight incremental expansion in standalone profitability. In a competitive generic formulations landscape, holding bottom-line margins firm provides defense against sector-wide raw material cost pressures.

Market Implications

The steady performance underpins stability in generic drug contract manufacturing. Investors will monitor full consolidated figures and margin commentary during the upcoming management earnings call for further details on volume throughput.

Trading Signals

Market Bias: Bullish

Positive net profit growth of ₹18.05 crore versus ₹17.80 crore YoY signals underlying earnings stability for Windlas Biotech.

Overweight: Pharmaceutical CDMO, Generic Formulations

Trigger Factors:

• Consolidated revenue growth commentary in earnings call
• Raw material cost trends and EBITDA margin trajectory

Time Horizon: Near-term (0-3 months)

Industry Context

Contract Development and Manufacturing Organizations (CDMO) in India continue to see consistent demand as domestic pharmaceutical brands outsource complex solid oral dosage and formulation processing to streamline supply chains.

Key Risks to Watch

• Input active pharmaceutical ingredient (API) cost fluctuations.
• Customer concentration risks in specific contract formulation orders.

Recent Developments

Windlas Biotech submitted its Q2 and H1 investor presentation to stock exchanges on November 5, 2026, following a board meeting notice issued on October 30, 2026.

Closing Insight

Consistent earnings performance reinforces Windlas Biotech's position as a reliable contract manufacturer, offering defensive stability within the mid-cap healthcare landscape.

High Performance Trading with SAHI.